Supercharge Your Innovation With Domain-Expert AI Agents!

Pharmaceutical composition containing L-DNA

A technology of L-NDA and -D-DNA, which is applied in the field of pharmaceutical compositions containing L-DNA, and can solve problems such as unfavorable pharmacokinetics

Inactive Publication Date: 2014-01-01
福尔克尔·A·埃德曼
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A disadvantage in the therapeutic application of aptamers is that they have unfavorable pharmacokinetics, i.e. they are decomposed very quickly, for example by endogenous nucleases (endogene Nukleasen)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing L-DNA
  • Pharmaceutical composition containing L-DNA
  • Pharmaceutical composition containing L-DNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Embodiment 1: cracking test

[0070] The activity of L-ribozyme and D-ribozyme was measured under various conditions. The basic conditions are as follows. Incubate 0.2 μM target RNA or DNA with 10 μl reaction mixture in 50 mM Tris-HCL buffer, pH 7.5, 20°C for 2 hours in the presence of 2 μM DNase or RNase (so DNase or RNase / target ratio of 10:1). Prior to the reaction, the target RNA or DNA and DNase or RNase were denatured at 72°C for 2 minutes and cooled slowly (1°C / min) to 25°C in a heat seal. Study Mg at concentrations of 0.1-10 mM 2+ - The effect of ions. Lysates were separated by 20% polyacrylamide gel electrophoresis in 0.09 Tris-borate buffer, pH 8.3, in the presence of 7 M urea. Fluorescence analysis was performed on a Phosphoimager Fuji Film FLA 5100. Data were acquired using the program Fuji analysis program. Graphs were made using Excel.

Embodiment 2

[0071] Embodiment 2: the preparation of target sequence and ribozyme

[0072] All target sequences were prepared by chemical synthesis. The purity of the synthesized product is greater than 90%.

[0073] As the DNase or RNase, the variable region of the DNase or RNase is selected around the cleavage site trimer according to the target sequence, and the RNase sequence or DNase sequence is synthesized. The purity of the synthesized product is greater than 85%.

[0074] All synthetic products were labeled with fluorescein at the 5'-end.

Embodiment 3

[0075] Example 3: Measuring activity in cells

[0076] According to the protocol, HeLa cells were transfected with 1 μg EGFP plasmid. Incubation was performed with 25, 50 or 100 nM solutions of the DNase or RNase used. After 24 h or 48 h, the cells were analyzed with a Leica microscope, or the fluorescence intensity (RFU) was measured according to the protocol with the aid of Multi-Mode Microplate Reader Synergy-2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of an L-DNA which is capable of binding to an L-RNA, in particular in an antisense reaction, and optionally of cleaving the L-RNA in the range of a target sequence of the L-RNA, for preparing a pharmaceutical composition for the treatment of undesired physiological side reactions due to the administration of a therapeutic molecule containing the L-RNA. The L-DNA can alternatively also be used for cleaving an endogenous target RNA or DNA.

Description

field of invention [0001] The present invention relates to a pharmaceutical composition containing L-DNA, the application of L-DNA for preparing the pharmaceutical composition, and a method for preparing the pharmaceutical composition. Background technique [0002] Aptamers are typically double-stranded D-nucleic acids that specifically bind to arbitrary target molecules, resembling an antibody / antigen-reaction (Ellington, A.D. et al. Nature 346:818-822 (1990)). Aptamers specific for a given target molecule are isolated for example from nucleic acid libraries by the SELEX-method (Tuerk, C. et al., Science 249:505-510 (1990)). [0003] In the therapeutic field, aptamers also have the purpose of binding undesired metabolites and thereby inhibiting them. Here, for example, only the gene products of oncogenes are mentioned. A disadvantage in therapeutic applications of aptamers is that they have unfavorable pharmacokinetics, ie are broken down very quickly, for example by endo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113
CPCC12N2320/30C12N15/113C12N2310/113C12N2310/32C12N2310/127C12N2330/30C12N15/11C12N15/111A61P39/02A61K48/00
Inventor 福尔克尔·A·埃德曼
Owner 福尔克尔·A·埃德曼
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com